'Love's labours lost': Failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa

Lancet

Volumn 350, Issue 9081, 1997, Pages 880-882

  Robbins, John B ^a   Towne, David W ^a   Gotschlich, Emil C ^b   Schneerson, Rachel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

AFRICA SOUTH OF THE SAHARA; ANTIBODY PRODUCTION; BACTERIAL COLONIZATION; CHILD; DRUG EFFICACY; EPIDEMIC; EPIDEMIC MENINGITIS; HEALTH CARE DELIVERY; HEALTH PROGRAM; HUMAN; MALI; NIGERIA; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION;

EID: 0030870627     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03227-3     Document Type: Note

References (41)

1. WHO Expert Committee on Biological Standardization. Requirements for meningococcal polysaccharide vaccine. World Health Organ Tech Rep Ser 1977; 610: 50-75.
2. Greenwood BM, Bradley AK, Blakebrough IS, Wali S, Whittle HC. Meningococcal disease and season in sub-Saharan Africa. Lancet 1984; ii: 1339-42.
3. Pinner RW, Onyango F, Perkins BA, et al. Kenya Centres for Disease Control Meningitis Study Group. Epidemic meningococcal disease in Nairobi, Kenya. J Infect Dis 1989; 166: 359-64.
4. Novelli VM, Lewis RG, Dagwood ST. Epidemic group A meningococcal meningitis in Haj pilgrims. Lancet 1987; ii: 863.
5. Denamur E, Pautard JC, Ducroix JP, et al. Meningococcal disease due to group A Neisseria meningitidis in contacts of Mecca pilgrims. Lancet 1987; ii: 1211.
6. Cochi SL, Markowitz LE, Joshi DD, et al. Control of epidemic group A meningococcal meningitis in Nepal. Int J Epidemiol 1987; 16: 91-97.
7. Goldschneider I, Artenstein MS, Gotschlich EC. Immunity to the meningococcus. J Exp Med 1969; 129: 1307-26.
8. Wahdan MH, Rizk F, El-Akkad AM, et al. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ 1973; 48: 667-73.
9. Wahdan MH, Sallam SA, Hassan MN, et al. A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull World Health Organ 1977; 55: 645-51.
10. Erwa HH, Haseeb MA, Idris AA, Lapeyssonnie L, Sandbornand WR, Sippel JE. A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A. Bull World Health Organ 1973; 49: 301-05.
11. Ettori D, Saliou P, Renadet J, Stoekel P. The type A polysaccharidic antimeningococcal vaccine: first controlled field trials in west Africa. Med Trop 1977; 225: 30.
12. Mäkelä PH, Käyhty H, Weckström P, Sivonen A, Renkonen O-V. Effect of group A meningococcal vaccine in army recruits in Finland. Lancet 1975; ii: 883-86.
13. Peltola H. Group A meningococcal polysaccharide vaccine and course of group A meningococcal epidemic in Finland. Scand J Infect Dis 1978; 10: 41-44.
14. de Oliveira CB, Taunay A deE, de Cruz TA, Galvao PA. Meningococcal meningitis in Sao Paulo, Brazil. Bol Oficina Sanit Panam 1975; 79: 54-62.
15. Jamba G, Bytchenko B, Causse G, et al. Immunization during a cerebrospinal meningitis epidemic in the Mongolian People's Republic. Bull World Health Organ 1979; 57: 943-46.
16. Greenwood BM, Hassan-King M, Whittle HC. Prevention of secondary cases of meningococcal disease in household contacts by vaccination. BMJ 1978; 1: 1317-19.
17. Zangwill K-M, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994; 169: 847-52.
18. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccaride vaccines in infants. J Clin Invest 1975; 56: 1536-47.
19. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J Infect Dis 1979; 140: 690-97.
20. Peltola H, Mäkelä PH, Käyhy H, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297: 686-91.
21. Lennon D, Gellin B, Hood D, Voss L, Heffernan H, Thakur S. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr Infect Dis J 1992; 11: 617-23.
22. Guirgis N, Schneerson R, Bax A, et al. Escherichia coli K51 and K93 capsular polysaccharides cross-reactive with group A meningococcal polysaccharide: immunochemical, structural and epidemiological studies. J Exp Med 1985; 162: 1837-51.
23. Peltola H, Kataja JM, Mäkelä PH. Shift in the age distribution of meningococcal disease as predictor of an epidemic? Lancet 1982; ii: 595-97.
24. Sanborn WR, Bencic Z, Cvjetanovic B, Gotschlich EC, Pollock TM, Sippel JE. Trial of a serogroup A meningococcus polysaccharide vaccine in Nigeria. Prog Immunobiol Standard 1972; 5: 497-505.
25. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; ii: 114-18.
26. Greenwood BM, Wali SS. Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet 1980; i: 729-32.
27. Binkin N, Band J. Epidemic of meningococcal meningitis in Bamako, Mali: epidemio logical features and analysis of vaccine efficacy. Lancet 1982; ii: 315-18.
28. Bosmans E, Vimont-Vicary P, Andre FE, Crooy PJ, Roelants P, Vandepitte J. Protective efficacy of a bivalent (A+C) meningococcal vaccine during a cerebrospinal meningitis epidemic in Rwanda. Ann Soc Belg Méd Trop 1980; 60: 297-306.
29. Mohammed I, Zaruba K. Control of epidemic meningococcal meningitis by mass vaccination. Lancet 1981 ; ii: 80-82.
30. Greenwood BM, Smith AW, Hassan-King M, et al. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, west Africa. Trans R Soc Trop Med Hyg 1986; 80: 1006-07.
31. Spiegel A, Greindl Y, Lippeveld T, et al. Effet de deux stratégies de vaccination sur l'évolution de l'épidemiede méningite à méninggocoque A survenue à N'Djamena (Tchad) en 1988. Bull World Health Organ 1993; 71: 311-15.
32. Hassan-King MKA, Walland RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect 1988; 16: 55-59.
33. Baudon D, Yankalbe M, Lois JP, Spiegel A, Guelina A. Strategie vaccination antimeningococcique: relefexions prelininaries a propos de le lépidemie de meningite cerebro-spinales au Tchad (Fevrier-Mai 1988). OCEAE Le bulletin de liaison et de documentation. OCEAE, 1988: 51-52.
34. Moore PS, Toole MJ, Nieburg P, Wladman RH, Broome CV. Surveillance and control of meningococcal meningitis epidemics in refugee populations. Bull World Health Organ 1990; 68: 587-96.
35. WHO. Cerebrospinal meningitis in the Central African Republic. Wkly Epidemiol Rec 1992; 67: 333-40.
36. Lengeler C, Kessler W, Daugla D. The 1990 meningococcal meningitis epidemic of Sarh (Chad): how useful was an earlier mass vaccination? Acta Tropica 1995; 59: 211-22.
37. Haelterman E, Boelaert M, Suetens C, Blok L, Henkens M, Toole MJ. Impact of a mass vaccination campaign against a meningitis epidemic in a refugee camp. Trop Med Int Health 1996; 1: 385-93.
38. Greenwood BM. Selective primary health care: strategies for control of disease in the developing world. XIII: acute bacterial meningitis. Rev Infect Dis 1984; 6: S374-S389.
39. Claesson BA, Trollfors B, Anderson PW, et al. Serum antibodies in six-year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 1996; 15: 170-72.
40. van Alphen L, Spanjaard L, vander Ende A, Schuurman I, Dankert J. National-wide decline of Haemophilus influenzae type b meningitis in the Netherlands after four-fold infant vaccination with conjugate vaccine, despite lack of herd immunity. J Pediatr (in press).
41. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995; 171: 1387-98.